Reports Q2 revenue $327M, consensus $311.49M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Our second quarter results demonstrate disciplined execution and increasingly profitable growth across our business-growing cash flow, earnings and operating income while absorbing the impact from last year’s portfolio transitions. With the majority of our businesses outperforming and targeted actions underway to strengthen commercial execution in Interventional Technologies, we are firmly on track to deliver our updated fiscal year 2026 guidance and long-range plan objectives. Our strong balance sheet will enable additional avenues for value creation, including advancing growth initiatives, debt repayment, and share buybacks.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics (HAE) Q2 Earnings Cheat Sheet
- Haemonetics: Strategic Adjustments and Growth Potential Justify Buy Rating Despite Revenue Challenges
- Haemonetics price target lowered to $64 from $78 at Citi
- Haemonetics Poised for Recovery and Growth: Buy Rating Affirmed Amid Strategic Actions and Strong Segment Performance